Effect of angiotensin II on hematopoietic progenitor cell proliferation

Stem Cells

Volumn 18, Issue 4, 2000, Pages 287-294

  Rodgers, K E ^a,b   Xiong, S ^a   Steer, R ^a   DiZerega, G S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Livingston Research Center   (United States)

Author keywords

Angiotensin; Erythroid; Hematopoietic; In vitro; Myeloid

Indexed keywords

ANGIOTENSIN; COLONY STIMULATING FACTOR; ERYTHROPOIETIN; LOSARTAN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CELL STIMULATION; COLONY FORMING UNIT; CONTROLLED STUDY; ERYTHROID CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOCYTE; MEGAKARYOCYTE; MESENCHYME; MOUSE; NONHUMAN; STROMA CELL; UMBILICAL CORD BLOOD;

ANIMALIA; MURINAE; TRIXIS;

EID: 0033855018     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-4-287     Document Type: Article

References (28)

1. Traycoff CM, Cornetta K, Yoder MC et al. Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential. Exp Hematol 1996;24:299-306.
2. Emerson SG. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood 1996;87:3082-3088.
3. Alcorn MJ, Holyake TL. Ex vivo expansion of haemopoietic progenitor cells. Blood Rev 1996;10:167-176.
4. Holyoake TL, Freshney MG, McNair L et al. Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood 1996;87:4589-4595.
5. Rodgers KE, Abiko M, Girgis W et al. Acceleration of dermal tissue repair by angiotensin II. Wound Repair and Regeneration 1997;5:175-183.
6. Rodgers KE, DeCherney AH, St. Amand KM et al. Histologic alterations in dermal repair after thermal injury: effects of topical angiotensin II. J Burn Care Rehabil 1997;18:381-388.
7. Mrug M, Stopka T, Julian BA et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997;100:2310-2314.
8. Haywood GA, Gullestad L, Tomohiro K et al. AT1 and AT2 Angiotensin receptor gene expression in human heart failure. Circulation 1997;95:1201-1206.
9. lo marrow cells. Blood 1995;86:548-556.
10. Stouffer GA, Owens GK. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta. Circ Res 1992;70:820-828.
11. Nakahara K, Nishimura H, Kuro-o M et al. Identification of three types of PDGFA chain gene transcripts in rabbit vascular smooth muscle and their regulated expression during development and by angiotensin II. Biochem Biophys Res Commun 1992;184:811-818.
12. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
13. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990;137:7-12.
14. Dzau VE, Pratt R, Gibbons G et al. Molecular mechanism of angiotensin in the regulation of vascular and cardiac growth. J Mol Cell Cardiol 1989;21(suppl III):S7.
15. Berk BC, Vekshtein V, Gordon HM et al. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-314.
16. Kawahara Y, Sunako M, Tsuda T et al. Angiotensin II induces expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988;150:52-59.
17. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
18. + mobilization and protein kinase C activation. J Biol Chem 1989;264:526-530.
19. Julian BA, Brantley Jr RR, Barker CV et al. Losartan, and angiotensin II type I receptor antagonist, lowered hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998;9:1104-1108.
20. Ducloux D, Fournier V, Bresson-Vautrin C et al. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int 1998;11:312-315.
21. Haznedaroglu IC, Buyukasik Y. Current evidence for the existence of a local renin-angiotensin system affecting physiological and pathological haemopoiesis in the bone marrow. Br J Haematol 1997;99:471.
22. Haznedaroglu IC, Tuncer S, Gursoy M. A local reninangiotensin system in the bone marrow. Med Hypothesis 1996;46:507-510.
23. Schilling H, Scheler F. Angiotensin-converting enzyme inhibition: side effects and risks. Z Kardiol 1998:77(suppl 3):47-54.
24. Weber MA. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med 1988;84:16-23.
25. Gleason MM, Roloff JS, Cyran SE et al. Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21. Pediatr Cardiol 1993;14:227-229.
26. Holland M, Stobie D, Shapiro W. Pancytopenia associated with administration of captopril to a dog. J Am Vet Assoc 1996;208:1683-1686.
27. Brogden RN, Todd PA, Sorkin EM. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988;36:540-600.
28. Chisi JE, Wdzieczak-Bakala J, Theirry J et al. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. STEM CELLS 1999;17:339-344.